Results 31 to 40 of about 1,091,305 (371)

A Polymerase-chain-reaction Assay for the Specific Identification of Transcripts Encoded by Individual Carcinoembryonic Antigen (CEA)-gene-family Members [PDF]

, 1993
Carcinoembryonic antigen (CEA) is a tumor marker that belongs to a family of closely related molecules with variable expression patterns. We have developed sets of oligonucleotide primers for the specific amplification of transcripts from individual CEA ...
Ang, Berling, Bernards, Chi, Chomczynski, Chomczynski, Daniel, F. Kommoss, Fainstein, Hinoda, Hinoda, J. Thompson, Khan, Kim, Kuroki, Lathe, Lucas, Motoyama, N. Beauchemin, Nagel, Neumaier, Ng, Oikawa, Ponte, Pèlegrin, Rooney, S. Mössinger, S. von Kleist, Sakuragi, Sambrook, Shively, Thompson, U. Engels, V. Reichardt, W. Zimmermann   +34 more
core   +1 more source

A Review of the Role of Carcinoembryonic Antigen in Clinical Practice

Annals of Coloproctology, 2019
Carcinoembryonic antigen (CEA) is not normally produced in significant quantities after birth but is elevated in colorectal cancer. The aim of this review was to define the current role of CEA and how best to investigate patients with elevated CEA levels.
C. Hall, L. Clarke, A. Pal, P. Buchwald, T. Eglinton, C. Wakeman, F. Frizelle   +6 more
semanticscholar   +1 more source

Significantly increased anti‐tumor activity of carcinoembryonic antigen‐specific chimeric antigen receptor T cells in combination with recombinant human IL‐12

Cancer Medicine, 2019
Chimeric antigen receptor T cells (CAR‐T cells) have been successfully used in treatments of hematological tumors, however, their anti‐tumor activity in solid tumor treatments was limited.
Xiaowei Chi, Peiwei Yang, Erhao Zhang, Jieyi Gu, Hui Xu, Mengwei Li, Xinmei Gao, Xin Li, Yinan Zhang, Hanmei Xu, Jialiang Hu   +10 more
semanticscholar   +1 more source

Prognostic significance of tumor microenvironment assessed by machine learning algorithm in surgically resected non‐small cell lung cancer

Cancer Reports, EarlyView., 2023
Abstract Background A methodology to assess the immune microenvironment (IME) of non‐small cell lung cancer (NSCLC) has not been established, and the prognostic impact of IME factors is not yet clear. Aims This study aimed to assess the IME factors and evaluate their prognostic values. Methods and Results We assessed CD8+ tumor‐infiltrating lymphocyte (
Yukihiro Terada, Mitsuhiro Isaka, Akira Ono, Takuya Kawata, Masakuni Serizawa, Keita Mori, Koji Muramatsu, Kiyoshi Tone, Hirotsugu Kenmotsu, Keiichi Ohshima, Kenichi Urakami, Takeshi Nagashima, Masatoshi Kusuhara, Yasuto Akiyama, Takashi Sugino, Toshiaki Takahashi, Yasuhisa Ohde   +16 more
wiley   +1 more source

Evaluation of some serum biochemical parameters of humans exposed to burnt tire emissions

Journal of Applied Sciences and Environmental Management, 2018
Evaluation of some serum biochemical parameters of humans who were exposed to burnt tire emissions (singeing process) was carried out in this study. Eighty (80) healthy adult males were recruited for the study after their consents were sought.
L.C. Chuku, B.M. Onyegeme-Okerenta, C Obia   +2 more
doaj   +1 more source

Prognostic significance of osteopenia in patients with colorectal cancer: A retrospective cohort study

Annals of Gastroenterological Surgery, 2021
Aim We examined the prognostic impact of osteopenia on the long‐term outcomes of patients with colorectal cancer after laparoscopic colectomy along with other nutritional factors, including sarcopenia or the Glasgow Prognostic Score.
Teppei Kamada, Kenei Furukawa, Junji Takahashi, Keigo Nakashima, Yuichi Nakaseko, Norihiko Suzuki, Masashi Yoshida, Hironori Ohdaira, Toru Ikegami, Yutaka Suzuki   +9 more
doaj   +1 more source

The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer [PDF]

, 2014
Objective In patients who have undergone a potentially curative resection of colorectal cancer, does a ‘second-look’ operation to resect recurrence, prompted by monthly monitoring of carcinoembryonic antigen, confer a survival benefit?Design A randomised
Bacon, Cochrane, Doshi, Ekman, Ellis, Embun, Fiorentino, Fiorentino, Fiorentino, Gill, Goldenberg, Grunhagen, Horton, Keep, Kraemer, Lennon, Levesque, Lewis, Loder, Mach, Mackay, Martin, Martin, Meeker, Moertel, Morris, Nicholson, Northover, Polk, Poston, Primrose, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2, Rosen, Searle, Staab, Treasure, Treasure, Treasure, Treasure, Utley, Wangensteen, Welch   +41 more
core   +1 more source

Tumor markers in breast cancer - European Group on Tumor Markers recommendations [PDF]

, 2005
Recommendations are presented for the routine clinical use of serum and tissue-based markers in the diagnosis and management of patients with breast cancer.
Abraha RS, Andreasen PA, Arie van Dalen, ASCO Expert Panel, Barak V, Barnes DM, Baselga J, Bast RC, Benraad TH, Bieglmayer C, Blamey RW, Bonadonna G, Chan DW, Chebil G, Chu KC, Colditz G, Conneely OM, De Koning H, Devine PL, Dixon AR, Dnistrian AM, Dnistrian AM, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Duffy MJ, Early Breast Cancer Trialist's, Early Breast Cancer Trialists Collaborative Group, Early Breast Cancer Trialists Collaborative Group, Easton DF, Ebeling FC, Ebeling FG, Eifel P, Einarsson R, Ekbom A, Elledge RM, Fisher B, Fitzgibbons PL, Gion M, Gion M, Guadagni F, Gyö, Harries M, Harvey JM, Helena Goike, Holli K, Holli K, Iwase H, Jager W, Jensen EV, Kamel EM, Konecny G, Kurebayashi J, Lamerz R, Leake R, Leers M, Leers MP, Leers MP, Legha SS, Leyland-Jones B, Look MP, Loomer L, Loprinzi CL, Madigan MP, Marius Nap, Massimo Gion, McCarty, McLaughlin R, Merimsky O, Michael J. Duffy, Mohsin SK, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Molina R, Morrow M, Nakata B, Newcomb P, Nicolini A, Nicolini A, Nicolini A, O'Hanlon DM, Paik S, Palazzo S, Parker SL, Parkin DN, Pecking AP, Pertschuk LP, Pertschuk LP, Petra Stieber, Piccart MJ, Price MR, Rafael Molina, Robertson JFR, Robertson JFR, Rogers CE, Roland Einarsson, Rolf Lamerz, Romer M, Rosselli del Turco M, Safi F, Schapira DV, Schapira DV, Sjostrom J, Slamon D, Soletormos G, Soletormos G, Soletormos G, Soletormos G, Stieber P, Sturgeon CM, Sweep CGJ, Tabar L, The GIVIO, The GIVIO, Theriault RL, Thorpe SM, Tomlinson IP, Tondini C, Van Dalen A, Van Dalen A, van Dalen A, van Dalen A, Van Dalen A, van Dalen A, Veronesi U, Vivian Barak, Vizcarra E, Vyzula R, Weihua Z, Williams MR, Yamauchi H, Zucchelli GC   +136 more
core   +1 more source

CEA, CYFRA 21-1, NSE, and ProGRP in the diagnosis of lung cancer: a multivariate approach [PDF]

, 2008
We retrospectively studied the single and combined diagnostic value of carcinoembryonic antigen (CEA), cytokeratin fragment 19 (CYFRA 21-1), neuron specific enolase (NSE) and pro-gastrin-releasing peptide (ProGRP), which were routinely analysed in ...
Barak, Barlesi, Bates, Chevret, Giovanella, Hammarstrom, Huang, Karnak, Kulpa, Lamy, Miyake, Molina, Muraki, Nisman, Paone, Pfister, Plebani, Pujol, Shibayama, Stieber, Stieber, Takada   +21 more
core   +1 more source

Towards understanding the mechanisms of actions of carcinoembryonic antigen‐related cell adhesion molecule 6 in cancer progression

Cancer Science, 2018
Human carcinoembryonic antigen (CEA) is the prototypic member of a family of highly related cell surface glycoproteins that includes carcinoembryonic antigen‐related cell adhesion molecule 6 (CEACAM6) and others.
Balsam Rizeq, Z. Zakaria, A. Ouhtit
semanticscholar   +1 more source